Showing results (1141-1150 of 3,857) with videos related to
Sort By:
Pageof 386
Cancer Cell|November 9, 2021
Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapyPaul Yenerall, Ralf Kittler, John MinnaCancer Cell|January 11, 2022
LTK fusions: A new target emerges in non-small cell lung cancerAlissa J Cooper, Lecia V Sequist, Ted W Johnson, et al.Cancer Cell|February 9, 2021
A Malignant Case of Arrested Development: Cancer Cell Dormancy Mimics Embryonic DiapauseYu-Hsuan Lin, Hao ZhuCancer Cell|February 9, 2021
Not All Tumor-Infiltrating CD8+ T Cells Are Created EqualWerner Held, Daniel E SpeiserCancer Cell|February 9, 2021
Heterogeneity in Metastatic Potential of Cancer Cells Is Revealed En MassePavitra Viswanath, Alana L WelmCancer Cell|September 24, 2019
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 MutantsChristopher A Eide, Matthew S Zabriskie, Samantha L Savage Stevens, et al.Cancer Cell|February 7, 2017
A UBE2O-AMPKα2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for TherapyIsabelle K Vila, Yixin Yao, Goeun Kim, et al.Cancer Cell|March 7, 2017
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell KillingJi Li, Nicola J Stagg, Jennifer Johnston, et al.Cancer Cell|February 16, 2017
Pheochromocytomas and Paragangliomas, Genetically Diverse and Minimalist, All at Once!Patricia L M DahiaCancer Cell|January 11, 2017
Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk NeuroblastomaVeronica Veschi, Zhihui Liu, Ty C Voss, et al.Pageof 386